Incidence and predictors of infections in patients with advanced non‐small cell lung cancer treated with checkpoint inhibitor immunotherapies: A monocentric retrospective cohort study
Davide Fiore Bavaro(Humanitas University), Domenico Galetta(Istituto Tumori Bari), Alessandra Belati(Humanitas University), Lucia Diella(Humanitas University), Pamela Pizzutilo(Istituto Tumori Bari), Francesco Pesola(Istituto Tumori Bari), Annamaria Catino(Istituto Tumori Bari), Annalisa Saracino(University of Bari Aldo Moro), Francesco Di Gennaro(University of Bari Aldo Moro), Nino Lamorgese(Istituto Tumori Bari), Vito Michele Garrisi(Istituto Tumori Bari), Ilaria Marech(University of Bari Aldo Moro), Fabio Signorile(University of Bari Aldo Moro)
Cited by 4
Related Papers
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2019|617
Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase–Producing <i>K. pneumoniae</i> Infections: A Retrospective Observational Multicenter Study
|Clinical Infectious Diseases|2021|264
Incidence of long COVID-19 in people with previous SARS-Cov2 infection: a systematic review and meta-analysis of 120,970 patients
|Internal and Emergency Medicine|2022|113